{"doi":"10.7326/m23-1915","title":"Trends in Primary Prevention Statin Use by Cardiovascular Risk Score From 1999 to 2018: A Repeated Cross-Sectional Study","abstract":"Letters5 December 2023Trends in Primary Prevention Statin Use by Cardiovascular Risk Score From 1999 to 2018: A Repeated Cross-Sectional StudyCasey J. Kim, MD, Jeremy B. Sussman, MD, MS, Kenneth J. Mukamal, MD, MPH, Micah Eades, MD, Timothy S. Anderson, MD, MASCasey J. Kim, MDDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, Jeremy B. Sussman, MD, MSDivision of General Medicine, University of Michigan, Ann Arbor, Michigan, Kenneth J. Mukamal, MD, MPHDivision of General Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, Micah Eades, MDVeterans Affairs Boston Healthcare System, West Roxbury, Massachusetts, Timothy S. Anderson, MD, MASDivision of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, and Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PennsylvaniaAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M23-1915 Annals Author Insight Video - Casey J. Kim, MD In this video, Casey J. Kim, MD, offers additional insight into the article, \"Trends in Primary Prevention Statin Use by Cardiovascular Risk Score From 1999 to 2018: A Repeated Cross-Sectional Study.\" (Duration 3:33) SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: In 2013, cholesterol treatment guidelines from the American College of Cardiology and the American Heart Association (ACC/AHA) (1) expanded statin eligibility for primary prevention on the basis of atherosclerotic cardiovascular disease (ASCVD) risk score compared with the 2002 Adult Treatment Panel III guidelines (1, 2). Previous studies have examined recent trends in statin use for primary prevention but have not assessed the effect of guideline changes (3). We hypothesized greater increases in statin use for primary prevention among adults newly recommended statins by the ACC/AHA guidelines.Objective: To describe trends in statin use for primary prevention across indication categories ...References1. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934. [PMID: 24239923] doi:10.1016/j.jacc.2013.11.002 CrossrefMedlineGoogle Scholar2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421. [PMID: 12485966] CrossrefMedlineGoogle Scholar3. Jacobs JA, Addo DK, Zheutlin AR, et al. Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol. 2023;8:443-452. [PMID: 36947031] doi:10.1001/jamacardio.2023.0228 CrossrefMedlineGoogle Scholar4. Chen TC, Clark J, Riddles MK, et al. National Health and Nutrition Examination Survey, 2015-2018: sample design and estimation procedures. Vital Health Stat 2. 2020:1-35. [PMID: 33663649] MedlineGoogle Scholar5. Tuzzio L, O'Meara ES, Holden E, et al. Barriers to implementing cardiovascular risk calculation in primary care: alignment with the consolidated framework for implementation research. Am J Prev Med. 2021;60:250-257. [PMID: 33279368] doi:10.1016/j.amepre.2020.07.027 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Casey J. Kim, MD; Jeremy B. Sussman, MD","journal":"Annals of Internal Medicine","year":2023,"id":327858,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":25,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9499,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":518204,"name":"Jeremy B. Sussman","orcid":"0000-0002-2158-3618","position":1,"is_corresponding":false},{"id":291349,"name":"Kenneth J. Mukamal","orcid":"0000-0001-8450-6970","position":2,"is_corresponding":false},{"id":1048667,"name":"M. Eades","orcid":"0000-0003-1996-6473","position":3,"is_corresponding":false},{"id":395133,"name":"Timothy S. Anderson","orcid":"0000-0002-5384-275X","position":4,"is_corresponding":false},{"id":806684,"name":"Casey Kim","orcid":"0000-0002-9404-5247","position":0,"is_corresponding":true}],"reference_count":7,"raw_metadata":null,"created_at":"2026-07-19T01:08:47.581262Z","pmid":"38048586","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}